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Background/Aims: Osteoporotic fractures are an important comorbidity with rheumatoid arthritis (RA). We
determined the overall fracture risk as assessed by the World Health Organization (WHO)'s FRAX tool in Korean
patients with seropositive RA. Additionally, we compared treatment eligibility according to the criteria of the Korean
Health Insurance Review Agency (HIRA), FRAX, and the National Osteoporosis Foundation (NOF).
Methods: Postmenopausal women and men ≥ 50 years of age with seropositive RA were recruited from one
rheumatism center in Korea. The FRAX score was estimated using the Japanese model. Patients were classified
as eligible for treatment using the HIRA, NOF, and FRAX thresholds for intervention.
Results: The study of 234 patients included 40 men (17%). The mean age was 60 ± 9 years, and 121 (52%)
patients had osteoporosis according to the WHO criteria. The overall median 10-year fracture risk was 13% for
major osteoporotic fractures and 3.5% for hip fractures. HIRA guidelines identified 130 patients (56%) eligible for
treatment, FRAX included 126 patients (54%), and 151 patients (65%) were included according to NOF
guidelines. Older patients with a greater number of risk factors were included by FRAX compared to HIRA. The
overall concordance between HIRA and FRAX, expressed as the kappa index, was 0.67, but was as low as 0.44
when limited to patients ≥ 60 years of age.
Conclusions: One-half of the patients had osteoporosis requiring treatment. RA patients have a high risk of
fracture, and the adoption of a risk-scoring system should be considered. (Korean J Intern Med 2010;25:436-
446)
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INTRODUCTION
Osteoporosis is approximately two times more
prevalent in patients with rheumatoid arthritis (RA)
than in the general population, and RA is associated
with a higher probability of fractures [1]. This is
thought to be related to accelerated bone resorption by
systemic and local inflammatory reactions, reduced
bone formation resulting from glucocorticoid use, and
limited exercise and activity owing to inflamed joints
[2]. Patients with RA have lower bone mineral density
(BMD) and a higher probability of bone fractures than
the general population when matched for age, gender,
and BMD [3]. In Korea, the Health Insurance Review
Agency (HIRA) identifies patients eligible for treatment
using a simplified method based on a minimum T-
score (-3.0) on a BMD examination or radiographic
evidence of osteoporotic fractures [4]. The fixed T-
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score-dependent threshold for intervention is a simple
and easy method for making national reimbursement
decisions, but it may not provide timely preventive
intervention for the high-risk group of patients with
RA. Furthermore, the difference in T-score threshold
criteria between HIRA and the World Health Organ-
ization (WHO) further confuses the issue. The HIRA
classification is based on a minimum T-score measured
at any lumbar or femur site, and identifies different
treatment populations than the method recommended
by the International Society for Clinical Densitometry
(ISCD), which designates the total lumbar, femur neck,
or total femur as proper sites for BMD measurement
[5]. 
Clinical risk factors are important predictors of the
probability of fragility fractures independent of BMD;
thus, the WHO developed the FRAX tool to assess the
10-year probability of fracture. It is based on a large-
scale, worldwide epidemiological study that included
the United Kingdom, United States, Australia, Japan,
and China [6]. This tool, which became available online
in 2008, is based on clinical risk factors, with or without
femur neck BMD measurement, and the outcome is the
probability of major osteoporotic or hip fractures in
individual patients in the next 10 years if not treated [7].
The WHO did not define the threshold for pharm-
acological intervention based on FRAX probabilities,
but recommended that the treatment threshold should
be defined by individual patients or national circumst-
ances. When no precise epidemiological model is
available, the WHO recommends use of the most
relevant model from similar racial or geographic
groups. In the United States, the National Osteoporosis
Foundation (NOF) revised its guidelines in 2008 and
recommended pharmacological intervention for
patients with low bone mass if the FRAX probabilities
were over a specific threshold and for a previously
identified population with defined osteoporosis or prior
osteoporotic fractures [8]. 
The present study aimed to determine the prevalence
of osteoporosis in Korean patients with RA using a
standard BMD examination and to compare the
Korean guidelines for osteoporosis treatment in
patients with RA with those of the FRAX tool. In
addition, we investigated the difference in the
treatment populations identified using the HIRA, NOF,
and FRAX tool with specific thresholds of risk as
defined in this study.
METHODS 
Patients 
In this cross-sectional epidemiological study, 234
consecutive patients with seropositive RA were
recruited from a single regional rheumatism center in
Korea between March and May 2010. The patients
fulfilled the American College of Rheumatology (ACR)
criteria for the diagnosis of RA with serological
evidence of rheumatoid factor. To maintain an
appropriate comparison, the patients were postmeno-
pausal women or men > 50 years of age as specified by
the FRAX and NOF guidelines [5,7,8]. Only patients
with BMD examination results available within 1 year
from the time of recruitment were included in the
study. The time period between serial BMD
examinations is usually more than 1 year as
recommended by the ISCD and Korean HIRA; thus, we
enrolled patients who had a BMD examination within 1
year from the time of recruitment to prevent unnecessary
EXCLUSION. 
Data collection
General characteristics including age, gender, body
weight, and height were collected by reviewing medical
charts. Patient interviews conducted by a physician
provided a history of osteoporotic fractures including
the hip, vertebrae, proximal upper arm, and distal
forearm; a parental history of hip fracture; smoking
status; and alcohol use status. The physician
determined the presence or absence of each risk factor
according to the FRAX criteria. Glucocorticoid use was
considered to be a risk factor if the patient had a history
of taking > 5 mg of a prednisone-equivalent dose of
glucocorticoids daily for > 3 months. X-rays of the
thoracic and lumbar vertebrae were reviewed to reveal
morphometric vertebral fractures. Disease duration
was calculated from symptom onset time to the date of
recruitment rather than from the date of diagnosis
because several patients were referred to our
rheumatism center with time gap between the date of
diagnosis and the actual onset of RA.
BMD interpretation 
The BMD examination results were reviewed
according to the ISCD guidelines. Secondary changes
in the lumbar area (L1 - L4) that produce false BMD
measurements, such as degenerative sclerotic changes,438 The Korean Journal of Internal Medicine Vol. 25, No. 4, December 2010
the presence of osteophytes, aortic calcifications,
collapsed compression fractures, and lumbar
prosthesis were discarded from the data [5,8]. The total
lumbar and lumbar minimum T-scores were recorded
following these exclusions. If only one vertebra
remained after the exclusions, the total lumbar T-score
was considered to be missing, but the minimum T-
score was recorded based on that vertebra. The same
exclusion method was used for the femur neck,
trochanter, intertrochanter, and Ward's triangle, and
then the T-scores of the femur neck, total femur, and
femur minimum were recorded. For Koreans, the
FRAX requires only raw BMD data from the femur
neck (g/cm
2) with the name of the manufacturer,
instead of the T-score. A fan-beam dual X-ray
absorptiometry unit (DXA, QDR-4500A; Hologic Inc.,
Bedford, MA, USA) was used to measure BMD. The
default diagnostic threshold for osteoporosis was a T-
score calculated from gender-matched BMD data in
young Asian adults derived in Japan [9]. After
acquisition of the BMD T-score, the patients were
classified as having osteoporosis if the T-score of the
total lumbar, femur neck, or total femur was ≤ -2.5
[10]. To determine the most prevalent site of
osteoporosis in patients with RA at the time of the
examination, lumbar and femur osteoporosis were
determined separately. 
FRAX tool application
No Korean epidemiological data for the FRAX
application are available; thus, we used the FRAX tool
on the Internet using a Japanese model (Fig. 1) [7]. We
used BMD raw data rather than the T-score and
entered individual patient values and clinical risk
factors with or without femur neck BMD measure-
ments. Because our study population was patients with
RA, the presence of secondary osteoporosis did not
have an additional effect on the risk estimation. The
output, 10-year probability of major osteoporotic and
hip fracture with or without BMD data, was recorded to
make a set of four probability scores for each individual.
The assessment of fracture risk was performed in
subgroups of age or gender. A previously defined risk
threshold for osteoporosis treatment in Korea was not
available; thus, we defined the threshold for pharmac-
ological intervention as ≥ 20% of major osteoporotic
fracture probability or ≥ 3% of hip fracture probability
in the next 10 years using the FRAX tool. This was the
same threshold specified by the NOF for patients with
low bone mass whose T-scores were between -1.0 and -
2.5.
NOF classification 
In 2008, the NOF described three categories of
patients eligible for pharmacological intervention [8]:
patients with prior osteoporotic hip or vertebral
fractures, patients classified as osteoporotic by the
WHO fixed T-score-based criteria, and patients with
low bone mass who had T-scores between -1.0 and -2.5
and a 10-year probability of ≥ 20% for major
osteoporotic fracture or ≥ 3% for hip fracture. In the
present study, the patients who fit any of these criteria
were considered to be eligible for treatment by NOF
criteria.
HIRA classification
Every Korean citizen is covered by the government
National Health Insurance and their eligibility for
reimbursement is reviewed by the HIRA [4]. HIRA
insurance coverage for osteoporosis requires a
minimum T-score of ≤ -3.0 at any site on the lumbar or
femur area, or radiographic evidence of an osteoporotic
fracture. 
Statistics
Dichotomous variables are expressed as the number
and percentage and continuous variables are expressed
as the mean and standard deviation (SD) or median
and range according to the fitness in a normal
distribution. Because the prevalence of osteoporosis
increases with age, we also analyzed the data in
Figure 1. FRAX data input form from the FRAX Website 
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subgroup patients ≤ 59 and ≥ 60 years of age, which
was the mean and median age of our entire cohort. The
prevalence of osteoporosis was calculated for the entire
population and for age and gender subgroups, and a
McNemar chi-square test was performed to compare
the lumbar and femur areas within each group [11].
Overall and within-treatment group based on HIRA
criteria, and the 10-year probability of major
osteoporotic and hip fractures with or without BMD
data were examined to determine the risk levels in
Korean patients with RA. The difference among
treatment groups classified using the HIRA, FRAX,
and NOF criteria was determined using a Venn
diagram to reveal the number of cases in each subset.
The demographic data and risk factors of the
discordant HIRA and FRAX populations were
statistically compared using the Mann-Whitney U test
for continuous variables or the chi-square test for
dichotomous variables.
Cohen’s kappa index was used to evaluate the
concordance between each system for pharmacological
intervention, and the grade of concordance was
considered high when the kappa index was > 0.8 and
good when it was > 0.6. The kappa index was used to
examine the data according to age to evaluate the grade
of discordance in the higher risk group of old age. The
data were analyzed using SPSS version 14.0 (SPSS Inc.,
Chicago, IL, USA), and p < 0.05 was deemed to be
statistically significant. All statistical comparisons were
based on two-sided tests. 
RESULTS
The study included 234 postmenopausal women or
men > 50 years of age with seropositive RA who were
recruited between March and May 2010. The patient
characteristics are shown in Table 1. The mean age was
60 ± 9 years. Spinal X-rays taken within 1 year from the
time of recruitment were available for 211 patients
(90.2%). The study population included 40 men (17%)
and 34 cases (15%) of prior osteoporotic fractures,
including 32 cases of vertebral fractures and two cases
of femur neck fractures. Table 2 shows the BMD T-
scores for the lumbar and femur areas and a
comparison of the minimum values from the entire
cohort and each age and gender subgroup. The T-
scores between the pair of total lumbar (L1 - L4) and
lumbar minimum and between the pairs of femur neck
or total femur and femur minimum were significantly
different (paired t test, p < 0.001). Women had lower
BMD T-scores compared to men in subgroup ≥ 60
years of age (t test, p < 0.005), but no difference was
found between women and men < 60 years of age. 
Table 3 shows the overall prevalence of osteoporosis
and osteopenia in the entire cohort and in the age and
gender subgroups. The results are based on the criteria
of a T-score ≤ -2.5 in the total lumbar, femur neck, or
total femur, as indicated by the WHO and ISCD
Table 1. Characteristics of patients with seropositive rheumatoid arthritis
All (n = 234) Male (n = 40) Female (n = 194)
Age, yr 60 ± 9 62 ± 9 60 ± 9
≤ 59  117 (50) 16 (40) 101 (52)
≥ 60  117 (50) 24 (60) 93 (48)
Male / Female  40 : 194 NA NA
Disease duration, mon  95 (3 - 571) 105 (6 - 519) 93 (3 - 571)
Body weight, kg  56 ± 9 61 ± 9 55 ± 8
Height, cm  157 ± 7 168 ± 6 155 ± 5
BMI, kg/m
2 22.5 ± 3.1 21.9 ± 3.1 22.6 ± 3.1
Smoker  20 (8.5) 10 (25) 10 (5.2)
Alcohol use
a 5 (2.1) 3 (7.5) 2 (1)
Steroid use
b 165 (70.5) 27 (67.5) 138 (71)
Past osteoporotic fracture  34 (14.5) 2 (5) 32 (17)
Parental hip fracture 4 (1.7) 0 4 (2)
Values are presented as the mean ± SD, median (range) or number (%).
NA, not applicable.
aIntake of three or more units of alcohol daily. A unit of alcohol varies from 8 to 10 g in different countries.
bExposure to oral glucocorticoids was defined as use of oral glucocorticoids for > 3 months  at a dose of prednisolone of 5 mg daily or more (or
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Table 2. T-score and femoral neck bone mineral density in patients with seropositive rheumatoid arthritis according to
overall, gender, and age groups
Lumbar total Lumbar Femoral neck Femur total Femur  Femoral neck
minimum
a minimum
b g/cm
2
All (n = 234) -2.0 ± 1.2 -2.4 ± 1.2 -2.1 ± 1.0 -1.5 ± 1.1 -2.7 ± 1.1 0.585 ± 0.111
Age ≤ 59 (n = 117) -1.8 ± 1.1 -2.1 ± 1.1 -1.7 ± 1.0 -1.1 ± 1.0 -2.1 ± 1.1 0.624 ± 0.105
Age ≥ 60 (n = 117) -2.3 ± 1.3 -2.7 ± 1.2 -2.4 ± 0.9 -1.8 ± 1.0 -3.2 ± 0.9 0.545 ± 0.103
Woman (n = 194) -2.2 ± 1.2 -2.5 ± 1.2 -2.2 ± 1.0 -1.5 ± 1.1 -2.7 ± 1.2 0.575 ± 0.112
Age ≤ 59 (n = 101) -1.8 ± 1.1 -2.1 ± 1.2 -1.7 ± 1.0 -1.1 ± 1.0 -2.1 ± 1.1 0.621 ± 0.108
Age ≥ 60 (n = 93) -2.6 ± 1.1 -2.9 ± 1.0 -2.6 ± 0.9 -1.9 ± 1.0 -3.3 ± 0.9 0.525 ± 0.094
Man (n = 40) -1.5 ± 1.3 -1.9 ± 1.3 -1.7 ± 0.8 -1.2 ± 0.8 -2.5 ± 0.8 0.631 ± 0.095
Age ≤ 59 (n = 16) -1.5 ± 0.9 -1.9 ± 0.9 -1.6 ± 0.7 -1.1 ± 0.8 -2.3 ± 0.7 0.644 ± 0.082
Age ≥ 60 (n = 24) -1.5 ± 1.6 -1.9 ± 1.5 -1.8 ± 0.8 -1.2 ± 0.9 -2.6 ± 0.9 0.623 ± 0.103
aMinimum T-score among L1 - L4.
bMinimum T-score among femoral neck, trochanter, intertrochanter, and Ward's triangle.
Table 3. Prevalence of osteoporosis in postmenopausal women and men > 50 years of age with seropositive
rheumatoid arthritis in overall, gender, and age groups 
Lumbar area Femur area Both areas Total  p value
a
All (n = 234)
Osteopenia  75 (32.1) 78 (33.3) 63 (26.9) 90 (38.5) NS
Osteoporosis  91 (38.9) 85 (36.3) 55 (23.5) 121(51.7) NS
Age ≤ 59 (n = 117)
Osteopenia  45 (38.5) 44 (37.6) 35 (29.9) 54 (46.2) NS
Osteoporosis  33 (28.2) 26 (22.2) 14 (12.0) 45 (38.5) NS
Age ≥ 60 (n = 117)
Osteopenia 30 (25.6) 34 (29.1) 28 (23.9) 36 (30.8) NS
Osteoporosis 58 (49.6) 59 (50.4) 41 (35) 76 (65) NS
Man (n = 40)
Osteopenia 19 (47.5) 24 (60) 18 (45) 25 (62.5) NS
Osteoporosis 7 (17.5) 5 (12.5) 1 (2.5) 11 (27.5) NS
Man, age ≤ 59 (n = 16)
Osteopenia 7 (43.8) 9 (56.3) 6 (37.5) 10 (62.5) NS
Osteoporosis 2 (12.5) 2 (12.5) 0 (0) 4 (25) NS
Man, age ≥ 60 (n = 24)
Osteopenia 12 (50.0) 15 (62.5) 12 (50.0) 15 (62.5) NS
Osteoporosis 5 (20.8) 3 (12.5) 1 (4.2) 7 (29.2) NS
Woman (n = 194)
Osteopenia 56 (28.9) 54 (27.8) 45 (23.2) 65 (33.5) NS
Osteoporosis 84 (43.3) 80 (41.2) 54 (27.8) 110 (56.7) NS
Woman, age ≤ 59 (n = 101)
Osteopenia 38 (37.6) 35 (34.7) 29 (28.7) 44 (43.6) NS
Osteoporosis 31 (30.7) 24 (23.8) 14 (13.9) 41 (40.6) NS
Woman, age ≥ 60 (n = 93)
Osteopenia 18 (19.4) 19 (20.4) 16 (17.2) 21 (22.6) NS
Osteoporosis 53 (57) 56 (60.2) 40 (43) 69 (74.2) NS
Values are presented as number (%).
NS, not significant.
aMcNemar chi-square test for the difference in prevalence of osteopenia and osteoporosis between the lumbar and area.Yoon J, et al. Osteoporosis in RA and treatment guidelines    441
guidelines. Overall, 52% of the patients were classified
as having osteoporosis and 39% were classified as
having osteopenia. When grouped by gender, the
prevalence of osteoporosis in women was 57%, but
men had a prevalence of only 28%. As expected, the
prevalence increased with age in women, but this
relationship was not evident in men in our study,
perhaps because of the small number of male patients
with RA. To determine the site-specificity of
osteoporosis in patients with RA, we compared
individual sites of osteoporosis in the lumbar and femur
areas. A McNemar chi-square test was performed to
evaluate the two correlated proportions [11]. Osteoporosis
was slightly more prevalent in the lumbar area than in
the femur area in women < 60 years of age, but the
difference was not significant (p= 0.248). 
The comparison of the WHO T-score system and the
HIRA minimum T-score system indicated that 110
patients (91%) among 121 patients classified as having
osteoporosis according to the WHO criteria could be
included in the treatment-eligible group using HIRA
criteria.
The overall median 10-year probability of major
osteoporotic and hip fracture based on femur neck
BMD was 13% and 3.5%, respectively (Table 4). This
was higher than the probability when femur neck BMD
was not evaluated. The HIRA treatment group had a
median probability of 21.5% for major osteoporotic
fractures and 7.5% for hip fractures. 
We used the HIRA and NOF criteria and the defined
threshold of FRAX with BMD to classify the patients as
eligible or not eligible for treatment (Fig. 2). As shown
in the diagram, 109 patients (47%) were included in the
treatment group by all three guidelines and 80 patients
(34%) were not eligible for treatment according to all
three guidelines. Fig. 3 shows the number patients
eligible for treatment in the FRAX and NOF compared
to those included using the HIRA criteria. The NOF
criteria included the largest number of patients in the
eligible for treatment group as it included 10% more
patients than HIRA and excluded 1.3% of patients
included by HIRA. The FRAX tool included 7.3% more
patients than HIRA, but excluded 9% of the patients
included in the HIRA treatment group. Thus, we found
a small but significant number of discordant
treatment-eligible patients based on the HIRA and
FRAX criteria (n = 38, 16.3%). The characteristics of
the mismatched patients in the HIRA and FRAX group
Table 4. Ten-year probability of fracture in postmenopausal women and men > 50 years of age with seropositive RA
Ten-year probability of osteoporotic fracture by FRAX, % 
Without BMD data With BMD data
Major osteoporotic fracture Hip fracture Major osteoporotic fracture Hip fracture
All patients (n = 234) 10 (2.3 - 70) 1.7 (0.1 - 55) 13 (2.3 - 85) 3.5 (0.1 - 78)
Patient group by HIRA agreement 
No (n = 104) 6.9 (2.3 - 30) 0.9 (0.1 - 13) 7.9 (2.3 - 33) 1.0 (0.1 - 12)
Yes (n = 130) 15 (3 - 70) 3.6 (0.3 - 55) 21.5 (5.4 - 85) 7.5 (0.4 - 78)
HIRA 
Yes and age ≤ 59 (n = 42)  9.3 (3 - 24) 1.2 (0.3 - 7.9) 14 (5.4 - 46) 4.2 (0.6 - 36)
HIRA
Yes and age ≥ 60 (n = 88) 19.5 (5.5 - 70) 6.1 (0.6 - 55) 28 (6.3 - 85) 9.6 (0.4 - 78)
Values are presented as median (range). 
RA, rheumatoid arthritis; BMD, bone mineral density; HIRA, Korean Health Insurance Review Agency.
Figure 2. Distribution of patients who met the Korean Health
Insurance Review Agency (HIRA), the National Osteoporosis
Foundation (NOF), and FRAX criteria for pharmacologic
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are shown in Table 5. The FRAX included more
patients who were older, male, cigarette smokers,
steroid users, taller, and had more clinical risk factors
compared to the HIRA. In contrast, the HIRA included
more patients who were younger, female, had lumbar
osteoporosis, and fewer risk factors. The men in our
study had a higher BMD than the women, and their
fracture risk was underestimated by the fixed T-score
assessment of the HIRA criteria. Thus, the higher BMD
in men who were excluded from the HIRA fixed T-
score system permitted inclusion in the group eligible
for treatment according to FRAX criteria (Table 5). 
The concordance between each guideline was
assessed using Cohen's kappa index. The values
showed overall fair concordance (0.67 - 0.78). As
expected by the differences in treatment eligibility
according to each guideline, HIRA had a lower kappa
index value for age > 60 years compared to the other
measures (0.44 with FRAX and 0.56 with NOF; Table
6). 
DISCUSSION
Our cross-sectional epidemiological study of Korean
postmenopausal women and men > 50 years of age
with seropositive RA found that approximately one-
half of the participants were osteoporotic according to
standard BMD measurements and the WHO criteria.
The number of patients considered eligible for treatm-
ent differed for each set of guidelines. Several patients
who had a high risk of fracture were not classified as
Figure 3. Comparison of the Korean Health Insurance Review
Agency (HIRA) and the National Osteoporosis Foundation
(NOF) or FRAX treatment groups. Compared to HIRA, the NOF
guidelines included 10.3% more patients in the eligible for
treatment group and the FRAX guidelines included 7.3% more
patients (exclusion mismatch, lighter area of bar). However, the
FRAX guidelines excluded 9% of the patients included by the
HIRA guidelines (inclusion mismatch, darker area of bar).
Table 5. Characteristics of the mismatched patients in the HIRA and FRAX guidelines 
Inclusion mismatch  Exclusion mismatch p value
b
(HIRA yes, FRAX no) (HIRA no, FRAX yes)
Cases, n (%)  21 (8.9) 17 (7.2)
Gender (M : F)  3 : 18 8 : 9 0.037
Age, yr  56 ± 6 66 ± 9 < 0.001
Body weight, kg 55 ± 7 60 ± 10 0.068  
Height, cm 157 ± 6 162 ± 8 0.036
BMI, kg/m
2  22.5 ± 3 23.2 ± 4.6 NS
Disease duration, mon 64 (12 - 156) 133 (6 - 519) 0.056
Smoker 1 6 0.031
Alcohol use 0 1 NS
Steroid use, n (%)  11 (52) 15 (88) 0.034
No. of clinical risk factors
a 1.6 ± 0.6 2.3 ± 0.8 0.007
other than age, gender, BMI
Lumbar osteoporosis, n (%)  15 (71) 1 (6 ) < 0.001
Femur osteoporosis, n (%)  3 (14) 3 (18) NS
The FRAX 10-year probability thresholds were ≥ 20% for major osteoporotic fracture and ≥ 3% for hip fracture.
HIRA, Korean Health Insurance Review; BMI, body mass index; NS, not significant.
aSum of seven dichotomous risk factors of 10 FRAX risk factors (use of steroids, history of past fragility fracture, parental history of hip fracture,
alcohol, smoking, rheumatoid arthritis, and secondary osteoporosis).
bThe Mann-Whitney U test was used for continuous variable and the chi-square exact test was used for dichotomous variables. Yoon J, et al. Osteoporosis in RA and treatment guidelines    443
eligible for treatment according to the fixed-T-score
system used by the HIRA, but were included when the
risk score system of the WHO and NOF was used. 
In the present study, we selected postmenopausal
women and men ≥ 50 years of age not only because
FRAX is intended for them but because the ISCD and
NOF recommend BMD measurements to determine
the risk of fractures in that population based on clinical
profile, whereas BMD in the general population is
measured only in postmenopausal women ≥ 65 years
of age or men ≥ 70 years of age [5]. Thus, the patients
in the current study may be representative of the RA
population with a fracture risk that requires evaluation
in daily practice.  
Rheumatoid factor positivity is associated with a
poor RA prognosis, and reduced bone mass is more
frequently found in patients with RA who are
seropositive than in those who are seronegative. One of
the goals of our study was to examine the relevance of
the various treatment-eligibility criteria for patients
with RA at high risk for a fracture; thus, we recruited
only the patients who were seropositive. Furthermore,
we are satisfied that the patients enrolled in the study
were homogeneous. 
The prevalence of osteoporosis in patients with RA
cannot be readily determined because each study
population has diverse characteristics regarding age
and gender, menopausal status in women, disease
activity, and disease duration. Moreover, the method
and the site of BMD examination are not standardized,
increasing the difficulty in making direct comparisons
between studies [2]. Joo et al. [12] estimated the
prevalence of osteoporosis in 134 Korean patients with
RA to be 13.4% (age range, 21 to 80 years). The
prevalence was 28.8% in the 59 postmenopausal
women included in their study. They reported 88.8%
rheumatoid factor positivity compared to the 100%
positivity we observed in the present study. Joo et al.
[12] conducted their study prior to development of the
current ISCD guidelines, and total lumbar BMD was
measured only in the L2 - L4 area, excluding the L1
area. Furthermore, BMD was measured at the neck,
trochanter, and Ward's triangle of the femur, which is
not an indexed area according to the current WHO
criteria. However, the prevalence of osteoporosis
reported by Joo et al. [12] was similar to that found in
another cohort in which approximately 30% of older
patients or postmenopausal women were classified as
having osteoporosis [2]. Clearly, additional studies on
osteoporosis in Korean patients with RA are warranted.
An Italian multicenter study of 925 patients with RA, of
which 73% were postmenopausal women, reported the
prevalence of lumbar and femur osteoporosis as 28.8%
and 36.2%, respectively [1]. The Norwegian national
registry cohort, thought to be free of selection bias,
included 394 patients with RA between the ages of 20
and 74 years. The prevalence of osteoporosis in the
lumbar and femur areas of this cohort was reported to
be 16.8% and 14.7%, respectively, and when the
analysis was limited to patients > 60 years of age, the
Table 6. Kappa index values between HIRA and NOF, HIRA and FRAX, and NOF and FRAX
HIRA FRAX  NOF 
All patients (n = 234) 
HIRA 1.0 0.67  0.76 
FRAX  1.0 0.78 
NOF  1.0 
Patients ≤ 59 yr (n = 117) 
HIRA 1.0  0.68  0.80 
FRAX  1.0 0.64 
NOF  1.0 
Patients ≥ 60 yr (n = 117) 
HIRA 1.0  0.44  0.56 
FRAX  1.0 0.80 
NOF  1.0 
p < 0.001 for all kappa indexes.
HIRA, Korean Health Insurance Review Agency; NOF, National Osteoporosis Foundation.444 The Korean Journal of Internal Medicine Vol. 25, No. 4, December 2010
prevalence was 31.5% and 28.6%, respectively [13]. The
overall prevalence of osteoporosis in either the lumbar
or femur area was not reported in the Norwegian study.
In our study of patients with RA who were seropositive
and had a mean age of 60 years, the prevalence of
osteoporosis in the lumbar and femur areas was 38.9%
and 36.3%, respectively, but the prevalence of
osteoporosis in either area was 51.7%. Note that a
significant percentage of the patients in our study were
in the transitional period in which they had
osteoporotic BMD in one area only. Recently, the
Korean government, Korean Ministry of Health,
Welfare and Family (MHW), and the Centers for
Disease Control and Prevention (CDC) initiated a
national survey of the prevalence of osteoporosis; the
first report was released in December 2009 based on
the results of the survey in 2008 with more than 4000
respondents [14]. The report indicated that the overall
prevalence of osteoporosis was 19.3% among people ≥
50 years of age and that the prevalence of osteoporosis
was as high as 32.6% in postmenopausal women in the
general population regardless of risk factors. Our study
was directly comparable to this survey in several ways:
the diagnosis of osteoporosis was based on the WHO
criteria using the standard diagnostic method of BMD
measurement, the government survey employed the
same device to measure BMD and standard BMD data
from young Asian adults was used for the T-score, and
the study population was postmenopausal women and
men > 50 years old. The higher prevalence of osteopor-
osis in our study may have occurred because many of
our patients were in the transitional stage between
osteoporosis in one area to that in both the lumbar and
femur, and because the prevalence of osteoporosis
among postmenopausal women in the general
population exceeds 30% prevalence if the current
criteria and standard methods of BMD are applied.
In the present study, the FRAX Japanese model was
selected because no epidemiological FRAX data for a
Korean cohort exist. The FRAX for the Japanese model
was constructed by the Hiroshima cohort and validated
by the Miyama cohort [15]. The WHO recommends the
application of FRAX based on a country's own
epidemiological model, but if one is not available, they
recommend use of the most suitable model of the
geographically nearest location or racial similarity. By
changing the epidemiological data, the relative
attribution of each clinical risk factor to the probability
of fractures would be maintained, but the absolute risk
would change. The absolute risk of fracture, as
represented by 10-year probability, is highest in the
Swedish and American models, high in the United
Kingdom and Italian models, and moderate in the
Chinese, Spanish, French, and Japanese models. The
lowest output of risk was shown in the Turkish model
[16]. Which FRAX country model is the most
appropriate to estimate the risk of fracture in the
Korean population is not yet known. We used the
Japanese model as one of the nearest countries with
similar ethnicity. 
The HIRA has adopted a simple fixed T-score system
to select patients eligible for pharmacological
intervention. However, the minimum T-score
threshold has been criticized for having a lower score (-
3.0) than the standard T-score used by the WHO (-2.5),
and for producing unreliable data at the different
measurement sites. The difference between the
threshold for diagnosis and threshold for treatment
was not based on the exact cost-effectiveness data. The
present study found no significant difference between
guidelines in the number of patients with RA who were
eligible for treatment: the HIRA criteria included
55.6% of the patients, and 51.7% of the patients were
classified as having osteoporosis using the WHO
criteria. This finding may be explained by the use of a
minimum T-score in any lumbar or femur site rather
than a standard site as specified by the WHO criteria.
Furthermore, the current HIRA policy includes
patients with prior osteoporotic fractures. Thus, the
total number of patients deemed eligible for
osteoporosis treatment may not differ between
guidelines; the more significant issue is the composit-
ion of the target treatment group. In addition to BMD,
the risk of fragility fracture increases with age, prior
fracture history, use of corticosteroids, and the
presence of RA [3]. Thus, while the FRAX estimated
risk for patients with RA may not be completely
accurate for the Korean population, risk factors other
than BMD should be considered when planning
preventive intervention for osteoporosis. Our
comparison of the FRAX and HIRA criteria in patients
with RA has demonstrated that high-risk patients, such
as those who are older or use steroids, may be
overlooked in the current system based on T-score
alone.
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ended by the NOF in the United States and other
countries as an ideal tool for fracture risk assessment in
patients with low bone mass, it has some barriers to
application in practice as previously noted [17]. One
limitation is its complexity. Several reports suggest that
a simplified FRAX or alternative scoring system be
used in practice [17,18]. An additional problem is that
the size of the treatment group has increased. After
modification of the NOF guidelines with FRAX in the
United States, the widespread adoption of new
guidelines was estimated to result in recommending
pharmacological treatment for at least 72% of US
white women ≥ 65 years of age and 93% of those ≥ 75
years of age, which is a larger inclusion than prior
guidelines [19]. To decrease the extra cost of applying
new inclusion, some trade-off between low-risk and
high-risk treatment groups must exist; however, this
may not be acceptable because the critical T-score is
still the strongest predictor for fractures. 
Alternatively, the economic problem may be
alleviated by using the FRAX as an assessment tool to
select patients for a BMD examination. Treating high-
risk patients without a BMD examination and selecting
an intermediate risk group for a BMD examination
may be more cost-effective than recommending BMD
measurements for all patients [20]. 
In the present study, we examined the discrepancy
originating from the BMD difference between the
lumbar and femur areas when FRAX was applied to the
previous HIRA treatment group. We identified 15
patients (6%) with high femur neck BMD who were not
classified as eligible for treatment despite having a low
lumbar area BMD. Without treatment, these patients
are at significant risk during the transient period when
they show only one area of osteoporosis. The FRAX
criteria use femur neck BMD as a reference because it
is a reliable marker for osteoporotic fractures in other
areas, and it is the strongest predictor for hip fractures
[3]. Fusiwara et al. [15] showed the validity of using the
femur neck BMD in FRAX to predict major
osteoporotic fractures other than femur fractures in the
Japanese model. 
In the present study, we could not examine the
validity of FRAX to predict fracture risk of Korean
patients with RA, but we could examine the feasibility
of the risk score system compared to the present T-
score system for threshold of intervention. We also
compared the size of the treatment group identified by
each system.  
In conclusion, nearly one-half of postmenopausal
women and men > 50 years of age with seropositive RA
in Korea have osteoporosis requiring treatment.
Because the current fixed T-score-dependent
classification excludes high-risk patients from
pharmacological intervention, the adoption of a risk
scoring system should be considered to prevent RA
comorbidities. Further studies are needed to validate
an osteoporosis risk scoring system for Koreans.
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